COVID-19 Impact on Global Elvitegravir Combination Drugs Market Size, Status and Forecast 2020-2026

July 2020 | 95 pages | ID: CF03596F8EBDEN
QYResearch

Abstracts

This report focuses on the global Elvitegravir Combination Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Elvitegravir Combination Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Gilead Sciences
• Bristol-Myers Squibb
• Janssen Pharmaceutica (Johnson & Johnson)
• Biocon Limited
• Flamingo Pharmaceuticals Limited
• IPCA Laboratories
• Medisist Pharma
• Affine Formulations Limited

Market segment by Type, the product can be split into

• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug
• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Combination Drug

Market segment by Application, split into

• Hospital
• Clinic
• Drug Center
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Elvitegravir Combination Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Elvitegravir Combination Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Elvitegravir Combination Drugs are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Elvitegravir Combination Drugs Revenue
1.4 Market Analysis by Type
  1.4.1 Global Elvitegravir Combination Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug
  1.4.3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Combination Drug
1.5 Market by Application
  1.5.1 Global Elvitegravir Combination Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Drug Center
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Elvitegravir Combination Drugs Industry Impact
  1.6.1 How the Covid-19 is Affecting the Elvitegravir Combination Drugs Industry
    1.6.1.1 Elvitegravir Combination Drugs Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Elvitegravir Combination Drugs Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Elvitegravir Combination Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Elvitegravir Combination Drugs Market Perspective (2015-2026)
2.2 Elvitegravir Combination Drugs Growth Trends by Regions
  2.2.1 Elvitegravir Combination Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Elvitegravir Combination Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Elvitegravir Combination Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Elvitegravir Combination Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Elvitegravir Combination Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Elvitegravir Combination Drugs Players by Market Size
  3.1.1 Global Top Elvitegravir Combination Drugs Players by Revenue (2015-2020)
  3.1.2 Global Elvitegravir Combination Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Elvitegravir Combination Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Elvitegravir Combination Drugs Market Concentration Ratio
  3.2.1 Global Elvitegravir Combination Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Elvitegravir Combination Drugs Revenue in 2019
3.3 Elvitegravir Combination Drugs Key Players Head office and Area Served
3.4 Key Players Elvitegravir Combination Drugs Product Solution and Service
3.5 Date of Enter into Elvitegravir Combination Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Elvitegravir Combination Drugs Historic Market Size by Type (2015-2020)
4.2 Global Elvitegravir Combination Drugs Forecasted Market Size by Type (2021-2026)

5 ELVITEGRAVIR COMBINATION DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Elvitegravir Combination Drugs Market Size by Application (2015-2020)
5.2 Global Elvitegravir Combination Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Elvitegravir Combination Drugs Market Size (2015-2020)
6.2 Elvitegravir Combination Drugs Key Players in North America (2019-2020)
6.3 North America Elvitegravir Combination Drugs Market Size by Type (2015-2020)
6.4 North America Elvitegravir Combination Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Elvitegravir Combination Drugs Market Size (2015-2020)
7.2 Elvitegravir Combination Drugs Key Players in Europe (2019-2020)
7.3 Europe Elvitegravir Combination Drugs Market Size by Type (2015-2020)
7.4 Europe Elvitegravir Combination Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Elvitegravir Combination Drugs Market Size (2015-2020)
8.2 Elvitegravir Combination Drugs Key Players in China (2019-2020)
8.3 China Elvitegravir Combination Drugs Market Size by Type (2015-2020)
8.4 China Elvitegravir Combination Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Elvitegravir Combination Drugs Market Size (2015-2020)
9.2 Elvitegravir Combination Drugs Key Players in Japan (2019-2020)
9.3 Japan Elvitegravir Combination Drugs Market Size by Type (2015-2020)
9.4 Japan Elvitegravir Combination Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Elvitegravir Combination Drugs Market Size (2015-2020)
10.2 Elvitegravir Combination Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Elvitegravir Combination Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Elvitegravir Combination Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Elvitegravir Combination Drugs Market Size (2015-2020)
11.2 Elvitegravir Combination Drugs Key Players in India (2019-2020)
11.3 India Elvitegravir Combination Drugs Market Size by Type (2015-2020)
11.4 India Elvitegravir Combination Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Elvitegravir Combination Drugs Market Size (2015-2020)
12.2 Elvitegravir Combination Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Elvitegravir Combination Drugs Market Size by Type (2015-2020)
12.4 Central & South America Elvitegravir Combination Drugs Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Gilead Sciences
  13.1.1 Gilead Sciences Company Details
  13.1.2 Gilead Sciences Business Overview and Its Total Revenue
  13.1.3 Gilead Sciences Elvitegravir Combination Drugs Introduction
  13.1.4 Gilead Sciences Revenue in Elvitegravir Combination Drugs Business (2015-2020))
  13.1.5 Gilead Sciences Recent Development
13.2 Bristol-Myers Squibb
  13.2.1 Bristol-Myers Squibb Company Details
  13.2.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  13.2.3 Bristol-Myers Squibb Elvitegravir Combination Drugs Introduction
  13.2.4 Bristol-Myers Squibb Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.2.5 Bristol-Myers Squibb Recent Development
13.3 Janssen Pharmaceutica (Johnson & Johnson)
  13.3.1 Janssen Pharmaceutica (Johnson & Johnson) Company Details
  13.3.2 Janssen Pharmaceutica (Johnson & Johnson) Business Overview and Its Total Revenue
  13.3.3 Janssen Pharmaceutica (Johnson & Johnson) Elvitegravir Combination Drugs Introduction
  13.3.4 Janssen Pharmaceutica (Johnson & Johnson) Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.3.5 Janssen Pharmaceutica (Johnson & Johnson) Recent Development
13.4 Biocon Limited
  13.4.1 Biocon Limited Company Details
  13.4.2 Biocon Limited Business Overview and Its Total Revenue
  13.4.3 Biocon Limited Elvitegravir Combination Drugs Introduction
  13.4.4 Biocon Limited Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.4.5 Biocon Limited Recent Development
13.5 Flamingo Pharmaceuticals Limited
  13.5.1 Flamingo Pharmaceuticals Limited Company Details
  13.5.2 Flamingo Pharmaceuticals Limited Business Overview and Its Total Revenue
  13.5.3 Flamingo Pharmaceuticals Limited Elvitegravir Combination Drugs Introduction
  13.5.4 Flamingo Pharmaceuticals Limited Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.5.5 Flamingo Pharmaceuticals Limited Recent Development
13.6 IPCA Laboratories
  13.6.1 IPCA Laboratories Company Details
  13.6.2 IPCA Laboratories Business Overview and Its Total Revenue
  13.6.3 IPCA Laboratories Elvitegravir Combination Drugs Introduction
  13.6.4 IPCA Laboratories Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.6.5 IPCA Laboratories Recent Development
13.7 Medisist Pharma
  13.7.1 Medisist Pharma Company Details
  13.7.2 Medisist Pharma Business Overview and Its Total Revenue
  13.7.3 Medisist Pharma Elvitegravir Combination Drugs Introduction
  13.7.4 Medisist Pharma Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.7.5 Medisist Pharma Recent Development
13.8 Affine Formulations Limited
  13.8.1 Affine Formulations Limited Company Details
  13.8.2 Affine Formulations Limited Business Overview and Its Total Revenue
  13.8.3 Affine Formulations Limited Elvitegravir Combination Drugs Introduction
  13.8.4 Affine Formulations Limited Revenue in Elvitegravir Combination Drugs Business (2015-2020)
  13.8.5 Affine Formulations Limited Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Elvitegravir Combination Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Elvitegravir Combination Drugs Revenue
Table 3. Ranking of Global Top Elvitegravir Combination Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Elvitegravir Combination Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug
Table 6. Key Players of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Combination Drug
Table 7. COVID-19 Impact Global Market: (Four Elvitegravir Combination Drugs Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Elvitegravir Combination Drugs Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Elvitegravir Combination Drugs Players to Combat Covid-19 Impact
Table 12. Global Elvitegravir Combination Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Elvitegravir Combination Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Elvitegravir Combination Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Elvitegravir Combination Drugs Market Share by Regions (2015-2020)
Table 16. Global Elvitegravir Combination Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Elvitegravir Combination Drugs Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Elvitegravir Combination Drugs Market Growth Strategy
Table 22. Main Points Interviewed from Key Elvitegravir Combination Drugs Players
Table 23. Global Elvitegravir Combination Drugs Revenue by Players (2015-2020) (Million US$)
Table 24. Global Elvitegravir Combination Drugs Market Share by Players (2015-2020)
Table 25. Global Top Elvitegravir Combination Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Elvitegravir Combination Drugs as of 2019)
Table 26. Global Elvitegravir Combination Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Elvitegravir Combination Drugs Product Solution and Service
Table 29. Date of Enter into Elvitegravir Combination Drugs Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 32. Global Elvitegravir Combination Drugs Market Size Share by Type (2015-2020)
Table 33. Global Elvitegravir Combination Drugs Revenue Market Share by Type (2021-2026)
Table 34. Global Elvitegravir Combination Drugs Market Size Share by Application (2015-2020)
Table 35. Global Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 36. Global Elvitegravir Combination Drugs Market Size Share by Application (2021-2026)
Table 37. North America Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 39. North America Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 40. North America Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 41. North America Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 42. North America Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 43. Europe Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 45. Europe Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 47. Europe Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 49. China Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 50. China Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 51. China Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 52. China Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 53. China Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 54. China Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 55. Japan Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 57. Japan Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 59. Japan Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 63. Southeast Asia Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 65. Southeast Asia Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 67. India Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 68. India Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 69. India Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 70. India Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 71. India Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 72. India Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Elvitegravir Combination Drugs Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Elvitegravir Combination Drugs Market Share (2019-2020)
Table 75. Central & South America Elvitegravir Combination Drugs Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Elvitegravir Combination Drugs Market Share by Type (2015-2020)
Table 77. Central & South America Elvitegravir Combination Drugs Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Elvitegravir Combination Drugs Market Share by Application (2015-2020)
Table 79. Gilead Sciences Company Details
Table 80. Gilead Sciences Business Overview
Table 81. Gilead Sciences Product
Table 82. Gilead Sciences Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 83. Gilead Sciences Recent Development
Table 84. Bristol-Myers Squibb Company Details
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Product
Table 87. Bristol-Myers Squibb Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Janssen Pharmaceutica (Johnson & Johnson) Company Details
Table 90. Janssen Pharmaceutica (Johnson & Johnson) Business Overview
Table 91. Janssen Pharmaceutica (Johnson & Johnson) Product
Table 92. Janssen Pharmaceutica (Johnson & Johnson) Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 93. Janssen Pharmaceutica (Johnson & Johnson) Recent Development
Table 94. Biocon Limited Company Details
Table 95. Biocon Limited Business Overview
Table 96. Biocon Limited Product
Table 97. Biocon Limited Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 98. Biocon Limited Recent Development
Table 99. Flamingo Pharmaceuticals Limited Company Details
Table 100. Flamingo Pharmaceuticals Limited Business Overview
Table 101. Flamingo Pharmaceuticals Limited Product
Table 102. Flamingo Pharmaceuticals Limited Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 103. Flamingo Pharmaceuticals Limited Recent Development
Table 104. IPCA Laboratories Company Details
Table 105. IPCA Laboratories Business Overview
Table 106. IPCA Laboratories Product
Table 107. IPCA Laboratories Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 108. IPCA Laboratories Recent Development
Table 109. Medisist Pharma Company Details
Table 110. Medisist Pharma Business Overview
Table 111. Medisist Pharma Product
Table 112. Medisist Pharma Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 113. Medisist Pharma Recent Development
Table 114. Affine Formulations Limited Business Overview
Table 115. Affine Formulations Limited Product
Table 116. Affine Formulations Limited Company Details
Table 117. Affine Formulations Limited Revenue in Elvitegravir Combination Drugs Business (2015-2020) (Million US$)
Table 118. Affine Formulations Limited Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Elvitegravir Combination Drugs Market Share by Type: 2020 VS 2026
Figure 2. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug Features
Figure 3. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Combination Drug Features
Figure 4. Global Elvitegravir Combination Drugs Market Share by Application: 2020 VS 2026
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Drug Center Case Studies
Figure 8. Other Case Studies
Figure 9. Elvitegravir Combination Drugs Report Years Considered
Figure 10. Global Elvitegravir Combination Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Elvitegravir Combination Drugs Market Share by Regions: 2020 VS 2026
Figure 12. Global Elvitegravir Combination Drugs Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Elvitegravir Combination Drugs Market Share by Players in 2019
Figure 15. Global Top Elvitegravir Combination Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Elvitegravir Combination Drugs as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Elvitegravir Combination Drugs Revenue in 2019
Figure 17. North America Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Elvitegravir Combination Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Gilead Sciences Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 26. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Bristol-Myers Squibb Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 28. Janssen Pharmaceutica (Johnson & Johnson) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Janssen Pharmaceutica (Johnson & Johnson) Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 30. Biocon Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Biocon Limited Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 32. Flamingo Pharmaceuticals Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Flamingo Pharmaceuticals Limited Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 34. IPCA Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. IPCA Laboratories Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 36. Medisist Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Medisist Pharma Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 38. Affine Formulations Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Affine Formulations Limited Revenue Growth Rate in Elvitegravir Combination Drugs Business (2015-2020)
Figure 40. Bottom-up and Top-down Approaches for This Report
Figure 41. Data Triangulation
Figure 42. Key Executives Interviewed